TREMFYA FOR PSORIATIC ARTHRITIS
Janssen presented the new and long-term data of DISCOVER-1, DISCOVER-2, and COSMOS studies, demonstrating the long-term benefits of Tremfya on axial symptoms, radiographic progression, fatigue, pain, and work productivity.
Efficacy of Tremfya on joint and axial symptoms
Patients treated with Temfya showed improvement in joint, skin, enthesitis, dactylitis, spinal pain, and disease severity endpoints in patients with psoriatic arthritis. At week 100, 40% of patients achieved minimal disease activity (MDA), and 59% of patients had a Disease Activity Index for Psoriatic Arthritis (DAPSA) score of ≤14.
Less radiographic progression
DISCOVER-2 trial showed that after two years of treatment, there was a reduction in the structural damage caused by psoriatic arthritis.
Pain, fatigue, and work productivity
The DISCOVER and VOYAGE-2 studies demonstrated that patients treated with Tremfya improved fatigue compared to placebo.
DISCOVER-1 and DISCOVER-2 showed improvement in the pain compared to placebo. At week 8, 48% of patients achieved ≥20 percent improvement, and at week 16, 33% achieved ≥50 % improvement.
RINVOQ IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
AbbVie presented the positive Phase 3 SELECT-AXIS 2 trials of Rinvoq (upadacitinib) in patients with axial spondyloarthritis. SELECT-AXIS 2 includes two different studies - SELECT-AXIS 2 AS bDMARD-IR study, demonstrating the efficacy of Rinvoq in patients with ankylosing spondylitis (AS), and SELECT-AXIS 2 nr-axSpA study, showing the effectiveness in patients with non-radiographic axial spondyloarthritis (nr-axSpA).
In the SELECT-AXIS 2, a significant number of patients achieved the primary endpoint of ASAS 40 at week 14 compared to placebo (45 % versus 23%).
DEUCRAVACITINIB IN SLE
BMS announced the positive Phase 2 results of deucravacitinib in patients with moderate to severe systemic lupus erythematosus (SLE).
BMS announced that deucravacitinib met the primary endpoint of achieving SLE Responder Index-4 (SRI(4)) compared to placebo at week 32. Deucravacitinib 3 mg and deucravacitinib 6 mg showed significant improvement versus placebo (deucravacitinib 3 mg BID: 58.2%, deucravacitinib 6 mg BID: 49.5%, placebo: 34.4%). The primary endpoint was not met with 12 mg.
For pipeline, market overview, SLRs, and market access reports (syndicate and customized) please write to email@example.com
Visit FirstViewInsight for more details